Early effects of human papillomavirus vaccination in Belgium

European Journal of Cancer Prevention

Volumn 24, Issue 4, 2015, Pages 340-342

  Merckx, Mireille ^a,b   Broeck, Davy Vanden ^a   Benoy, Ina ^c   Depuydt, Christophe ^c   Weyers, Steven ^b   Arbyn, Marc ^d  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Sonic Health Care AML   (Belgium)

^d SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Adolescents; cervical cancer; HPV vaccine; HPV vaccine impact; surveillance

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BELGIUM; CANCER SCREENING; FEMALE; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; TREND STUDY; UTERINE CERVIX CANCER; VACCINATION; YOUNG ADULT; COHORT ANALYSIS; EARLY CANCER DIAGNOSIS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; POISSON DISTRIBUTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; ADULT; BELGIUM; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POISSON DISTRIBUTION; PREVALENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84930752776     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000067     Document Type: Article

References (15)

1. Arbyn M, Van Oyen H (2000). Cervical cancer screening in Belgium. Eur J Cancer 36:2191-2197.
2. Arbyn M, Simoens C, Van Damme P, Scharpantgen A, Meijer CJ, Beutels P (2010). Introduction of human papillomavirus vaccination in Belgium, Luxembourg and the Netherlands. Gynecol Obstet Invest 70:224-232.
3. Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, et al. (2012). EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 131:1969-1982.
4. Clifford GM, Smith JS, Aguado T, Franceschi S (2003). Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89:101-105.
5. FUTURE II Study Group (2007a). Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 196:1438-1446.
6. FUTURE II Study Group (2007b). Quadrivalent vaccine against human papillo-mavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915-1927.
7. Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M (2012). Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:781-789.
8. Micalessi IM, Boulet GA, Bogers JJ, Benoy IH, Depuydt CE (2011). High-throughput detection, genotyping and quantification of the human papillo-mavirus using real-time PCR. Clin Chem Lab Med 50:655-661.
9. Nelder JWR (1972). Generalized linear models. J R Stat Soc A 135:370-384.
10. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. HPV PATRICIA Study Group (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
11. Seoud M, Tjalma WA, Ronsse V (2011). Cervical adenocarcinoma: moving towards better prevention. Vaccine 29:9148-9158.
12. Simoens C, Sabbe M, Van Damme P, Beutels P, Arbyn M (2009). Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008. Euro Surveill 14:1-4.
13. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ (2006). HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 208:152-164.
14. Weyers S, Vanden Broeck D, Guieu A, Depuydt C, Temmerman M, Arbyn M (2013). Surveillance of Effects of Human Papillomavirus Immunisation in Belgium (SEHIB). Eurogin Abstracts Part 2. p.261.
15. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. (2012). Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:100-110.